Background It is probable but unproven that Epstein–Barrvirus (EBV) has a role in nasopharyngeal carcinoma. We determinedwhether antibodies against EBV are present before the developmentof nasopharyngeal carcinoma.
Methods A total of 9699 men were enrolled between 1984 and 1986.Blood samples were examined for IgA antibodies against EBV capsidantigen and neutralizing antibodies against EBV-specific DNase.During 131,981 person-years of follow-up, 22 pathologicallyconfirmed new cases of nasopharyngeal carcinoma that were diagnosedmore than one year after recruitment were ascertained throughlinkage with the National Cancer Registry of Taiwan.
Results The cumulative risk of nasopharyngeal carcinoma per100,000 person-years was 11.2 for subjects who tested positivefor neither serologic marker, 45.0 for those who had one marker,and 371.0 for those who had both markers. After adjustment forage and the presence or absence of a family history of nasopharyngealcarcinoma, the relative risk of nasopharyngeal carcinoma was32.8 for subjects with both markers (95 percent confidence interval,7.3 to 147.2; P<0.001) and 4.0 for subjects with one marker(95 percent confidence interval, 1.6 to 10.2; P=0.003), as comparedwith subjects with neither marker. The longer the duration offollow-up, the greater the difference in the cumulative incidenceof nasopharyngeal carcinoma between seropositive and seronegativesubjects.
Conclusions IgA antibodies against EBV capsid antigen and neutralizingantibodies against EBV DNase are predictive of nasopharyngealcarcinoma.
Source Information
From the Graduate Institute of Epidemiology, College of Public Health (Y.-C.C., H.Y., C.-J.C.), the Graduate Institute of Microbiology (J.-Y.C., C.-S.Y.), and the Department of Otolaryngology (M.-M.H.), College of Medicine, National Taiwan University, Taipei; and the Department of General Education, National Taipei College of Nursing, Taipei (M.-Y.L.) — all in Taiwan.
Address reprint requests to Dr. Chien-Jen Chen at the Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, 1 Jen-Ai Rd., Sec. 1, Taipei 100, Taiwan, or at cjchen{at}ha.mc.ntu.edu.tw.
Yang, P.-W., Chang, S.-S., Tsai, C.-H., Chao, Y.-H., Chen, M.-R.
(2008). Effect of phosphorylation on the transactivation activity of Epstein-Barr virus BMRF1, a major target of the viral BGLF4 kinase. J. Gen. Virol.
89: 884-895
[Abstract][Full Text]
Hsu, M., Wu, S.-Y., Chang, S.-S., Su, I.-J., Tsai, C.-H., Lai, S.-J., Shiau, A.-L., Takada, K., Chang, Y.
(2008). Epstein-Barr Virus Lytic Transactivator Zta Enhances Chemotactic Activity through Induction of Interleukin-8 in Nasopharyngeal Carcinoma Cells. J. Virol.
82: 3679-3688
[Abstract][Full Text]
Fachiroh, J., Prasetyanti, P. R., Paramita, D. K., Prasetyawati, A. T., Anggrahini, D. W., Haryana, S. M., Middeldorp, J. M.
(2008). Dried-Blood Sampling for Epstein-Barr Virus Immunoglobulin G (IgG) and IgA Serology in Nasopharyngeal Carcinoma Screening. J. Clin. Microbiol.
46: 1374-1380
[Abstract][Full Text]
Choong, N., Vokes, E.
(2008). Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer. CA Cancer J Clin
58: 32-53
[Abstract][Full Text]
Ho, C.-H., Hsu, C.-F., Fong, P.-F., Tai, S.-K., Hsieh, S.-L., Chen, C.-J.
(2007). Epstein-Barr Virus Transcription Activator Rta Upregulates Decoy Receptor 3 Expression by Binding to Its Promoter. J. Virol.
81: 4837-4847
[Abstract][Full Text]
Chang, E. T., Adami, H.-O.
(2006). The enigmatic epidemiology of nasopharyngeal carcinoma.. Cancer Epidemiol. Biomarkers Prev.
15: 1765-1777
[Abstract][Full Text]
Leung, D. T. M., van Maren, W. W. C., Chan, F. K. L., Chan, W. S., Lo, A. W. I., Ma, C. H., Tam, F. C. H., To, K. F., Chan, P. K. S., Sung, J. J. Y., Lim, P. L.
(2006). Extremely Low Exposure of a Community to Severe Acute Respiratory Syndrome Coronavirus: False Seropositivity due to Use of Bacterially Derived Antigens.. J. Virol.
80: 8920-8928
[Abstract][Full Text]
Fachiroh, J., Paramita, D. K., Hariwiyanto, B., Harijadi, A., Dahlia, H. L., Indrasari, S. R., Kusumo, H., Zeng, Y. S., Schouten, T., Mubarika, S., Middeldorp, J. M.
(2006). Single-Assay Combination of Epstein-Barr Virus (EBV) EBNA1- and Viral Capsid Antigen-p18-Derived Synthetic Peptides for Measuring Anti-EBV Immunoglobulin G (IgG) and IgA Antibody Levels in Sera from Nasopharyngeal Carcinoma Patients: Options for Field Screening. J. Clin. Microbiol.
44: 1459-1467
[Abstract][Full Text]
Butsch Kovacic, M., Martin, M., Gao, X., Fuksenko, T., Chen, C.-J., Cheng, Y.-J., Chen, J.-Y., Apple, R., Hildesheim, A., Carrington, M.
(2005). Variation of the Killer Cell Immunoglobulin-Like Receptors and HLA-C Genes in Nasopharyngeal Carcinoma. Cancer Epidemiol. Biomarkers Prev.
14: 2673-2677
[Abstract][Full Text]
Levin, L. I., Munger, K. L., Rubertone, M. V., Peck, C. A., Lennette, E. T., Spiegelman, D., Ascherio, A.
(2005). Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis. JAMA
293: 2496-2500
[Abstract][Full Text]
Tung, C. J., Wang, H. C., Lo, S. H., Wu, J. M., Wang, C. J.
(2004). In vivo dosimetry for external photon treatments of head and neck cancers by diodes and TLDS. Radiat Prot Dosimetry
111: 45-50
[Abstract][Full Text]
Lin, J.-C., Wang, W.-Y., Chen, K. Y., Wei, Y.-H., Liang, W.-M., Jan, J.-S., Jiang, R.-S.
(2004). Quantification of Plasma Epstein-Barr Virus DNA in Patients with Advanced Nasopharyngeal Carcinoma. NEJM
350: 2461-2470
[Abstract][Full Text]
Chang, Y., Chang, S.-S., Lee, H.-H., Doong, S.-L., Takada, K., Tsai, C.-H.
(2004). Inhibition of the Epstein-Barr virus lytic cycle by Zta-targeted RNA interference. J. Gen. Virol.
85: 1371-1379
[Abstract][Full Text]
Lo, S., Ho, W.-K., Wei, W. I.
(2004). Outcome of Patients With Positive Epstein-Barr Virus Serologic Status in the Absence of Nasopharyngeal Carcinoma in Hong Kong. Arch Otolaryngol Head Neck Surg
130: 770-772
[Abstract][Full Text]
Wong, T.-S., Kwong, D. L.-W., Sham, J. S.-T., Wei, W. I., Kwong, Y.-L., Yuen, A. P.-W.
(2004). Quantitative Plasma Hypermethylated DNA Markers of Undifferentiated Nasopharyngeal Carcinoma. Clin. Cancer Res.
10: 2401-2406
[Abstract][Full Text]
Leung, S.-f., Tam, J. S., Chan, A. T.C., Zee, B., Chan, L. Y.S., Huang, D. P., Van Hasselt, A., Johnson, P. J., Lo, Y.M. D.
(2004). Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein-Barr Virus DNA and Anti-Epstein-Barr Viral Capsid Antigen IgA Antibody. Clin. Chem.
50: 339-345
[Abstract][Full Text]
Cho, E.-Y., Hildesheim, A., Chen, C.-J., Hsu, M.-M., Chen, I-H., Mittl, B. F., Levine, P. H., Liu, M.-Y., Chen, J.-Y., Brinton, L. A., Cheng, Y.-J., Yang, C.-S.
(2003). Nasopharyngeal Carcinoma and Genetic Polymorphisms of DNA Repair Enzymes XRCC1 and hOGG1. Cancer Epidemiol. Biomarkers Prev.
12: 1100-1104
[Abstract][Full Text]
Levin, L. I., Munger, K. L., Rubertone, M. V., Peck, C. A., Lennette, E. T., Spiegelman, D., Ascherio, A.
(2003). Multiple Sclerosis and Epstein-Barr Virus. JAMA
289: 1533-1536
[Abstract][Full Text]
Hildesheim, A., Apple, R. J., Chen, C.-J., Wang, S. S., Cheng, Y.-J., Klitz, W., Mack, S. J., Chen, I-H., Hsu, M.-M., Yang, C.-S., Brinton, L. A., Levine, P. H., Erlich, H. A.
(2002). Association of HLA Class I and II Alleles and Extended Haplotypes With Nasopharyngeal Carcinoma in Taiwan. JNCI J Natl Cancer Inst
94: 1780-1789
[Abstract][Full Text]
Forastiere, A., Koch, W., Trotti, A., Sidransky, D.
(2001). Head and Neck Cancer. NEJM
345: 1890-1900
[Full Text]
Previous
